INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
1. Pomerantz LLP is investigating GSK for potential securities fraud. 2. GSK's stock fell 4.73% after FDA's unfavorable decision on Blenrep. 3. The investigation may impact investor confidence and GSK's market position. 4. Findings could lead to legal repercussions for GSK and its executives. 5. Investors can join the class action through Pomerantz LLP.